Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
Ardelyx (ARDX) presented results from its IBS in America 2024 supplemental survey at the American College of Gastroenterology's Annual Meeting. The nationwide online survey of over 280 IBS-C patients revealed significant impacts on quality of life, with 90% reporting negative effects on mental, emotional, and sexual health, relationships, and independence.
Key findings show that 85% of patients experienced rectal pain during bowel movements, 86% reported bloating, and 85% suffered from abdominal cramps. Over 45% of patients considered IBS-C a financial hardship. Among perimenopausal or menstruating respondents, over 80% reported menstruation worsened abdominal pain and bloating symptoms.
Ardelyx (ARDX) ha presentato i risultati del suo sondaggio supplementare sull'IBS in America 2024 durante l'Annual Meeting dell'American College of Gastroenterology. Il sondaggio online nazionale condotto su oltre 280 pazienti con IBS-C ha rivelato impatti significativi sulla qualità della vita, con il 90% che ha segnalato effetti negativi sulla salute mentale, emotiva e sessuale, sulle relazioni e sull'indipendenza.
I risultati chiave mostrano che l'85% dei pazienti ha sperimentato dolore rettale durante i movimenti intestinali, l'86% ha riferito gonfiore e l'85% ha sofferto di crampi addominali. Oltre il 45% dei pazienti ha considerato l'IBS-C un onere finanziario. Tra le rispondenti in perimenopausa o mestruazione, oltre l'80% ha riferito che le mestruazioni hanno aggravato il dolore addominale e i sintomi di gonfiore.
Ardelyx (ARDX) presentó los resultados de su encuesta suplementaria sobre el SII en América 2024 en la Reunión Anual del Colegio Americano de Gastroenterología. La encuesta en línea a nivel nacional, realizada con más de 280 pacientes con SII-C, reveló impactos significativos en la calidad de vida, con el 90% reportando efectos negativos en la salud mental, emocional y sexual, las relaciones y la independencia.
Los hallazgos clave muestran que el 85% de los pacientes experimentaron dolor rectal durante las deposiciones, el 86% reportaron hinchazón y el 85% sufrieron calambres abdominales. Más de el 45% de los pacientes consideraron que el SII-C representa una carga financiera. Entre las encuestadas en perimenopausia o menstruación, más de el 80% reportaron que la menstruación empeoró el dolor abdominal y los síntomas de hinchazón.
Ardelyx (ARDX)는 미국 소화기학회 연례 회의에서 IBS in America 2024 보충 조사 결과를 발표했습니다. 280명이 넘는 IBS-C 환자를 대상으로 한 전국 온라인 설문 조사에서 90%가 정신적, 감정적, 성적 건강, 관계 및 독립성에 부정적인 영향을 보고하는 등 삶의 질에 중대한 영향을 미친 것으로 나타났습니다.
주요 결과에 따르면 85%의 환자가 배변 시 직장 통증을 경험했으며, 86%는 팽만감을 느꼈고, 85%는 복통으로 고통받았습니다. 45% 이상의 환자가 IBS-C를 재정적 어려움으로 고려했습니다. 폐경 전 또는 월경 중인 응답자 중 80% 이상이 월경이 복통과 팽만 증상을 악화시켰다고 보고했습니다.
Ardelyx (ARDX) a présenté les résultats de son enquête complémentaire sur le SII en Amérique 2024 lors de la Réunion Annuelle du Collège Américain de Gastroentérologie. L'enquête en ligne à l'échelle nationale, menée auprès de plus de 280 patients atteints de SII-C, a révélé des impacts significatifs sur la qualité de vie, avec 90% des répondants signalant des effets négatifs sur la santé mentale, émotionnelle et sexuelle, les relations et l'indépendance.
Les principaux résultats montrent que 85% des patients ont ressenti des douleurs rectales lors des selles, 86% ont signalé des ballonnements et 85% ont souffert de crampes abdominales. Plus de 45% des patients ont considéré le SII-C comme un fardeau financier. Parmi les répondantes en périménopause ou menstruation, plus de 80% ont rapporté que les menstruations aggravaient les douleurs abdominales et les symptômes de ballonnements.
Ardelyx (ARDX) hat Ergebnisse seiner ergänzenden Umfrage zum IBS in Amerika 2024 auf dem Jahreskongress des American College of Gastroenterology vorgestellt. Die landesweite Online-Umfrage unter über 280 IBS-C Patienten offenbarte erhebliche Auswirkungen auf die Lebensqualität, wobei 90% negative Effekte auf die psychische, emotionale und sexuelle Gesundheit, Beziehungen und Unabhängigkeit berichteten.
Wichtige Erkenntnisse zeigen, dass 85% der Patienten während des Stuhlgangs rektale Schmerzen erlebten, 86% berichteten von Blähungen und 85% litten unter Bauchkrämpfen. Über 45% der Patienten betrachteten IBS-C als finanzielle Belastung. Unter den antwortenden Frauen in der Perimenopause oder Menstruation berichteten über 80%, dass die Menstruation die Bauchschmerzen und Blähungen verschlimmerte.
- None.
- None.
Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life
Survey results presented in two poster presentations
WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that results from the IBS in America 2024 supplemental survey, in partnership with Health Union, were presented at the American College of Gastroenterology’s (ACG) Annual Scientific Meeting & Postgraduate Course, currently taking place in Philadelphia. Developed as an online, nationwide survey conducted in partnership with Health Union, more than 280 irritable bowel syndrome with constipation (IBS-C) patients were surveyed to better understand their symptoms and the impact of IBS-C on their overall health and quality of life.
“Ardelyx is committed to better understanding the lived experience of patients with IBS-C, and the insights gained from our IBS in America supplemental survey clearly outline the everyday impact of IBS-C on patients, which extends far beyond constipation and results in a low quality of life for many patients,” said Johannah Ruddy, M.Ed, director, patient advocacy at Ardelyx. “The supplemental survey provides us with unique insights into what symptoms patients are experiencing, and how often. We hope these findings spark productive conversations between patients and their healthcare providers on how to recognize, understand and treat IBS-C to improve the lives of those living with this condition, and raise awareness of the need for broader dialogue around this condition.”
Notably,
A Media Snippet accompanying this announcement is available by clicking on this link.
Additional survey findings include:
85% of patients experienced pain in the rectum or anus while trying to have bowel movements- Over
55% of patients reported a feeling of incomplete bowel movement “often” or “always” in the previous seven days - Most of those surveyed experienced other symptoms in addition to constipation, including:
86% of patients experienced bloating85% of patients experienced abdominal cramps and pain64% of patients experienced fatigue
- Of the 104 respondents currently perimenopausal or having menstrual periods, more than
45% felt that menstruation made constipation worse, and over80% felt menstruation exacerbated abdominal pain and bloating symptoms - Over
45% of patients considered IBS-C “somewhat,” “quite a bit” or “very much” a financial hardship to themselves and their families
Data from the IBS in America 2024 supplemental survey was presented in two posters during ACG’s Annual Scientific Meeting this week, which are publicly available here.
Title: Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS In America 2024 Real-World Survey
Authors: Eric Shah, Johannah Ruddy, Belinda Gist, Elizabeth Stremke, Laura Williams, Baharak Moshiree
Poster Number: P0641
Title: Patients With Irritable Bowel Syndrome With Constipation From the IBS In America 2024 Real-World Survey Experience Burdensome Symptoms Beyond Constipation
Authors: Baharak Moshiree, Johannah Ruddy, Belinda Gist, Elizabeth Stremke, Laura Williams, Eric Shah
Poster Number: P2335
About Irritable Bowel Syndrome with Constipation (IBS-C)
Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.
About IBS in America 2024
IBS in America 2024 was a 15-minute, real-world, online survey fielded by Health Union from January 15 to April 14, 2024, in United States residents age 18 and older. The survey covered demographics, comorbidities, quality of life impact, treatments and health care provider (HCP) interactions. Patients who completed the survey were invited to participate in an institutional review board–approved supplemental extension survey if they met the following criteria: diagnosed with IBS-C or IBS with alternating diarrhea and constipation by an HCP, currently seeing an HCP to treat IBS, and had ever used an over the counter or prescription treatment for IBS.
Four questions addressed patients’ menstrual status and the impact of menstruation on constipation. These analyses only include patients diagnosed with IBS-C who completed the supplemental extension survey. Respondents with IBS-C (N=284) had a mean (range) age of 51 (18-86) years and were predominantly female (
About Health Union
Health Union is the proven industry leader in condition-specific, online health community and patient engagement. The company reaches millions of people through the largest network of online health communities (e.g., Migraine.com, MultipleSclerosis.net, LungCancer.net) and health leaders – addressing virtually every condition and providing patients and caregivers with the information, connection, and support they need to live better with challenging health conditions. For more than a decade, Health Union has been transforming the way pharmaceutical and healthcare brands engage with people, enabling transparent, innovative opportunities to gain insight and empower action through advertising, marketing research, and clinical trial solutions for the healthcare industry.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
What percentage of IBS-C patients reported negative life impacts in Ardelyx's 2024 survey?
What are the most common symptoms reported in Ardelyx's 2024 IBS-C survey?
How does menstruation affect IBS-C symptoms according to Ardelyx's 2024 survey?
What percentage of IBS-C patients consider it a financial hardship in the 2024 Ardelyx survey?
